Bionomics Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,206.60
16,949.40
16,592.40
6,749.60
25,085.60
Depreciation, Depletion & Amortization
1,500.90
1,713.50
1,937.60
1,742.60
1,667.80
Other Funds
94.70
4,654.20
2,871.10
5,993.90
3,050.20
Funds from Operations
4,802.20
10,909.40
12,204.50
773.70
22,135.30
Changes in Working Capital
17,148.10
16,786.10
1,922.70
1,012.10
2,251.20
Net Operating Cash Flow
12,345.90
5,876.70
14,127.20
238.40
19,884.10
Capital Expenditures
216.60
846.30
196.70
247.50
487.50
Sale of Fixed Assets & Businesses
-
-
68.60
-
-
Net Investing Cash Flow
216.60
1,237.40
128.10
247.50
487.50
Issuance/Reduction of Debt, Net
200.40
12,020.40
4,979.90
2,224.70
-
Net Financing Cash Flow
609.50
12,289.00
33,202.00
2,081.00
2,634.20
Net Change in Cash
11,950.80
16,945.20
18,937.80
2,576.70
17,943.20
Free Cash Flow
12,562.50
5,030.50
14,323.90
485.90
20,371.60
Deferred Taxes & Investment Tax Credit
-
327.70
420.80
213.20
1,767.80
Net Assets from Acquisitions
-
391.10
-
-
-
Change in Capital Stock
409.10
268.50
28,222.10
143.60
411.20
Exchange Rate Effect
2.20
16.90
8.90
9.80
205.90

About Bionomics

View Profile
Address
31 Dalgleish Street
Thebarton South Australia (SA) 5031
Australia
Employees -
Website http://www.bionomics.com.au
Updated 07/08/2019
Bionomics Ltd. is a clinical stage biopharmaceutical company, which discovers and develops therapeutics for cancer and diseases of the central nervous system. The company operates through following segments: Drug Discovery and Development, and Contract Services. The Drug discovery and development segment engages in the discovery, development and commercialization of compounds to match a target product profile.